Brainstorm Cell Therapeutics Inc.
1325 Avenue of Americas, 28th Floor
New York, NY 10019
August 17, 2021
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Brainstorm Cell Therapeutics Inc.: Registration Statement on Form S-3 filed August 9, 2021 (File No. 333- 258640)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Brainstorm Cell Therapeutics Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 19, 2021, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Jesse Nevarez of Goodwin Procter LLP at (212) 459-7327.
| Sincerely, | |
| Brainstorm Cell Therapeutics Inc. | |
| /s/ Chaim Lebovits | |
| Chaim Lebovits | |
| Chief Executive Officer and Principal Executive Officer |
cc: Jesse Nevarez, Esq., Goodwin Procter LLP